1 min read|55 words
A case-grounded AI agent has achieved high concordance with hematology tumor board recommendations across retrospective, external, and prospective clinical evaluations, according to Nature Medicine. The locally deployable system could standardize blood cancer treatment pathways and reduce care disparities globally. Read how this breakthrough advances AI in clinical oncology.
Read the full article on GMJ Newsroom →
Was this article helpful?
